(IN BRIEF) GSK licensor Hansoh Pharma has reported positive results from ARTEMIS-011, a pivotal phase III trial of risvutatug rezetecan, or Ris-Rez, in patients in China with relapsed osteosarcoma after at least two prior lines of systemic therapy. The trial … Read the full press release →
Posted in Business, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged ADC, advanced sarcoma, ARTEMIS-011, B7-H3, B7-H3-targeted antibody-drug conjugate, breakthrough therapy designation, cancer treatment, chemotherapy, CHINA, EMA, EMBOLD Sarcoma-202, ES SCLC, Europe, European Medicines Agency, extensive-stage small-cell lung cancer, FDA, GSK, GSK Highlights Growing Late-Stage Evidence for B7-H3-Targeted ADC Ris-Rez, GSK plc, Hansoh Pharma, Hansoh Pharmaceutical Group Co Ltd, Hansoh Pharma’s ARTEMIS-011 Trial Shows Progression-Free Survival Benefit for Ris-Rez, Hesham Abdullah, Japan, Japan Ministry of Health Labour and Welfare, lung cancer, metastatic sarcoma, monoclonal antibody, oncology, orphan drug designation, osteosarcoma, overall survival, PFS, phase Ib II trial, Phase III Trial, pivotal trial, PRIME designation, Priority Medicines, progression-free survival, prostate cancer, pulmonary neuroendocrine carcinoma, refractory osteosarcoma, relapsed osteosarcoma, Ris Rez, Ris-Rez Delivers Positive Phase III Outcomes in Relapsed Osteosarcoma and Small-Cell Lung Cancer, risvutatug rezetecan, SCLC, Small cell lung cancer, solid tumours, topoisomerase inhibitor payload, United Kingdom, United States, unresectable sarcoma, US Food and Drug Administration
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
